Abstracts Archive - Page 918 of 2425 - ACR Meeting Abstracts

Abstract Number: 2395 • 2019 ACR/ARP Annual Meeting
DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment
Theodore Pincus¹, jaquelin Chua ², Joel Block ² and Isabel Castrejon ², ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, chicago, IL
Background/Purpose: A study of patients with RA at their first visit to an academic rheumatology site indicated an unexpected observation that 75% of patients had…
Abstract Number: 2396 • 2019 ACR/ARP Annual Meeting
DNA Methylation of the Dual Specificity Phosphatase 22 (DUSP22) Gene Promoter in Plasma and Medication Use in Rheumatoid Arthritis (RA)
Lissette Delgado-Cruzata ¹, Milena Rodriguez Alvarez ², Abhimanyu Amarnani², Edgardo Guzman ³, Alorah Bliese ¹, Belen Albarracin ¹, Carl Cirilli ¹ and Shante Hinson ⁴, ¹John Jay College, City University of New York, New York, ²SUNY Downstate Medical Center, Brooklyn, ³Lincoln Medical & Mental Mental Health Center, Brooklyn, ⁴Lincoln Medical & Mental Mental Health Center, New York
Background/Purpose: The Dual Specificity Phosphatase 22 (DUSP22) gene expression has been shown to be regulated via DNA methylation of its promoter. In addition, aberrant DNA…
Abstract Number: 2397 • 2019 ACR/ARP Annual Meeting
Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer
Yoshinobu Koyama¹, Akemi Senoo ², Kaho Otsuki ³, Yoshiharu Sato ⁴, Mari Yamaguchi ² and Toshie Higuchi ¹, ¹Center for Autoimmune Diseases, Division of Rheumatology, Japanese Red Cross Okayama Hospital, Okayama, Japan, ²Division of Dermatology, Japanese Red Cross Okayama Hospital, Okayama, Japan, ³Center for Autoimmune Diseases, Division of Rheumatology, Okayama, Japan, ⁴DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: Skin lesion as a side effect of Tocilizumab (TCZ) has not been paid much attention. In the drug information sheets, incidence of dermatological adverse…
Abstract Number: 2398 • 2019 ACR/ARP Annual Meeting
Prevalence of Anxiety and Depression in a Cohort of Patients with Rheumatic Diseases on Biological Infusions
Alexander Peck¹, Ella Starobinska ², Gilbert Ortega ¹, Jaclyn Leong ¹, Travis Maestas ¹, Phan Saligrama ¹, Jawad Bilal ¹ and Dominick Sudano ³, ¹University of Arizona College of Medicine, Tucson, AZ, ²University of Arizona College of Medicine, Tucson, AL, ³Banner University Medical Center Tucson, Tucson
Background/Purpose: Studies have shown an increased prevalence of psychologic disorders in rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and psoriatic arthritis, compared to…
Abstract Number: 2399 • 2019 ACR/ARP Annual Meeting
Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis
Carlos Sánchez-Piedra¹, María Colazo ², Rosa Roselló ³, Cristina Campos ⁴, P. Vela ⁵, Cristina Bohorquez ⁶, Carolina Pérez-García ⁷, Manuel Pombo-Suarez ⁸, Carlos Fernández-López ⁹, Dolores Ruiz-Montesinos ¹⁰, Fernando Alonso ¹¹, Federico Diaz-Gonzalez ¹² and Juan Jesús Gómez-Reino ¹³, ¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²Hospital de Burgos, Burgos, ³Hospital San Jorge, Huesca, ⁴Hospital General de Valencia, Valencia, ⁵Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ⁶Universitary Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcala de Henares, Spain, ⁷Rheumatology, Hospital del Mar, Barcelona, Catalonia, Spain, ⁸Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ¹⁰Hospital Virgen Macarena, Sevilla, ¹¹Unidad Investigación SER, Madrid, Spain, ¹²Hospital de Canarias, Tenerife, ¹³Hospital de Santiago, Santiago de Compostela
Background/Purpose: During the past 15 years, advancements in the understanding of the safety and effectiveness, as well as the expanding access and availability of biologic…
Abstract Number: 2400 • 2019 ACR/ARP Annual Meeting
The Effect of Co-medication with Methotrexate and Other Conventional Synthetic Disease Modifying Anti-rheumatic Drugs on First Tumor Necrosis Inhibitor Drug Survival in Patients with Rheumatoid Arthritis: Results Form a Nationwide Registry
Herman Mann¹, Lucie Nekvindová ², Jakub Závada ³, Zlatuše Křístková ², Pavel Horák ⁴, Jiří Vencovský ¹ and Karel Pavelka ¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ²Institute of Biostatistics and Analyses Ltd., spinoff company of Masaryk University, Brno, Czech Republic, ³Institute of Rheumatology, Prague, Prague, Czech Republic, ⁴Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) should be used for the treatment of rheumatoid arthritis (RA) in combination with conventional synthetic disease modifying anti‑rheumatic drugs…
Abstract Number: 2401 • 2019 ACR/ARP Annual Meeting
Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate
Thierry Dervieux¹, Joel Kremer ², Kelley Brady ¹, Chihiro Takahashi ³, Tsutomu Takeuchi ⁴ and Yuko Kaneko ⁵, ¹Exagen, Vista, CA, ²Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, ³Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Keio University Hospital Division of Rheumatology, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is an anti-folate prodrug activated to MTX polyglutamates (MTXPGs). Japanese Rheumatoid Arthritis (RA) patients are thought to have heightened sensitivity to MTX…
Abstract Number: 2402 • 2019 ACR/ARP Annual Meeting
Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis?
Martin Schaefer¹, Jörn Kekow ², Karin Rockwitz ³, Anke Liebhaber ⁴, Angela Zink ⁵ and Anja Strangfeld ⁶, ¹German Rheumatism Research Center, Berlin, Germany, ²Otto von Guericke University Magdeburg and Helios Clinic Vogelsang-Gommern, Vogelsang-Gommern, Germany, ³Rheumatologist, Goslar, Germany, ⁴Rheumatologist, Halle/ Salle, Germany, ⁵German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, ⁶German Rheumatism Research Center (DRFZ), Berlin, Germany
Background/Purpose: The satisfaction of rheumatoid arthritis (RA) patients with their pharmacological therapy is a relevant patient reported outcome which influences treatment adherence and continuation. However,…
Abstract Number: 2403 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³ and Daisuke Kato ³, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in studies of Japanese, Korean and Taiwanese patients with RA. This analysis of…
Abstract Number: 2404 • 2019 ACR/ARP Annual Meeting
Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?
Iván de Jesús Hernández-Galarza ¹, Rita Pineda-Sic¹, Marielva Castro-Gonzalez ¹, Diana Elsa Flores-Alvarado ¹, Octavio Ilizaliturri-Guerra ¹, Rodolfo Uriarte-Botello ¹ and Dionicio Galarza-Delgado ¹, ¹Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Treatment adherence in Rheumatoid Arthritis (RA) patients vary from 30 to 80%. It is important to identify the associated factors to a low adherence,…
Abstract Number: 2405 • 2019 ACR/ARP Annual Meeting
Protein Biomarkers Predicting the Response to IFX+MTX+LEF Treatment in Patients with Rheumatoid Arthritis
Jian Chen ¹, Meng-shi Tang ², Li-chang Xu ³, Shu Li ², Yan Ge ², Jing Tian ², Xi Xie ², Jin-wei Chen ², Jin-feng Du ² and Fen Li¹, ¹Department of Rheumatology and Immunology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China, Changsha, ²Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, ³International Department of YALI High School, Changsha
Background/Purpose: Patients with rheumatoid arthritis (RA) usually receive triple therapy with methotrexate (MTX), leflunomide (LEF) and infliximab (IFX), but nearly one-third of them do not…
Abstract Number: 2406 • 2019 ACR/ARP Annual Meeting
Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry
Bente Glintborg ¹, Stylianos Georgiadis ², Mette Nørgaard ³, Frank Mehnert ³, Kathrine Lederballe Grøn ¹, Niels Steen Krogh ⁴ and Merete Lund Hetland¹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Zitelab / DANBIO, Copenhagen, Denmark
Background/Purpose: Marketing of biosimilar biological drugs may significantly reduce drug costs if comparable safety and efficacy of originator and the biosimilar can be documented. In…
Abstract Number: 2407 • 2019 ACR/ARP Annual Meeting
The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis
Kunihiro Yamaoka¹, Yoshiya Tanaka ², Hideto Kameda ³, Barbara Hendrickson ⁴, Sebastian Meerwein ⁵, Ying Zhang ⁴ and Tsutomu Takeuchi ⁶, ¹Kitasato University School of Medicine, Kanagawa, Japan, Kanagawa, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Toho University, Tokyo, Japan, Tokyo, Japan, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁶Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Upadacitinib (UPA) is an oral reversible JAK inhibitor engineered for greater selectivity for JAK1 versus JAK2, JAK3, and TYK2, and is currently being assessed…
Abstract Number: 2408 • 2019 ACR/ARP Annual Meeting
A Prospective Analysis of Factors Impacting Medication Decision-Making in Patients with Rheumatoid Arthritis
Elizabeth Salt¹, Amanda Wiggins ², Kristine Lohr ² and Mary Kay Rayens ², ¹University of Kentucky, Lexington, KY, ²University of Kentucky, Lexington
Background/Purpose: Prior research suggests that medication decision-making in rheumatoid arthritis (RA) patients is affected by disease activity, satisfaction with care, trust in their health care…
Abstract Number: 2409 • 2019 ACR/ARP Annual Meeting
24-hour Activity Profiling in People Living with Arthritis: Habits Matter
Lynne Feehan¹, Linda Li ¹, Na Lu ² and Hui Xie ³, ¹Arthritis Research Canada and University of British Columbia, Vancouver, Canada, Vancouver, BC, Canada, ²Arthritis Research Canada, Vancouver, Canada, Vancouver, BC, Canada, ³Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: Current practices promoting change in physical activity classify individuals as being more or less active. However, across 24-hours people spend time in different types…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].